Purpose: To report ritonavir-associated retinal pigment epithelium toxicity in a patient infected with the HIV on highly active antiretroviral therapy including ritonavir.
M
any medications have been associated with retinal toxicity. The retinal pigment epithelium is a likely target for systemically administered compounds, since the underlying choroid is highly vascularized. The blood-retinal barrier prevents many systemically administered drugs from entering the eye through the circulatory system. Yet many medications that are administered systemically may still gain access to the eye and evoke degeneration of the RPE, 1, 2 and have been associated with toxic retinopathy, 3, 4 optic neuritis, 5, 6 anterior uveitis, and cystoid macular edema. 7 We report a case of an HIV-positive patient, who presented ritonavir-associated toxicity mimicking retinitis pigmentosa after 8 years of continuous treatment.
Case Report
A 59-year-old HIV-infected male, presented with a history of slowly progressive decreased night vision in both eyes and peripheral visual field loss of 2 years duration. He had been placed on antiretroviral therapy with protease inhibitors ritonavir (Norvir, Abbott Laboratories, Maidenhead, United Kingdom) 100 mg/day and atazanavir (Reyataz) 300 mg/day, and a nucleoside reverse transcriptase inhibitor tenofovir/emtricitabine (Truvada, Gilead Sciences International Limited, Foster City, CA) 245/200 mg/day starting 8 years before, and other medications such as: reosuvastatin 10 mg/day, amlodopine 5 mg/day, and aspirin 75 mg/day. CD4 + T-cell count was 330 cells per microliter, viral load was undetectable, and there was no history of AIDS-defining illness. There was no record of previous didanosine use, nor of antituberculous drugs. The patient refers no family history of retinal disorders and has no history of HIV retinopathy or cytomegalovirus retinitis.
Best-corrected visual acuity measured 6/15 in the right eye and 6/9.5 in the left eye. Anterior segment examination and intraocular pressures were normal in both eyes. Dilated fundoscopic examination revealed scattered bone specule-like pigment changes on the mid-peripheral retina of both eyes (Figure 1, A and B) , whereas wide-field fundus autofluorescence revealed more extensive retinal involvement than stereo fundus biomicroscopy alone, highlighting mottled hypofluorescence, and sparing the macula area in the left eye ( Figure 1 , C and D).
A fluorescein angiogram was performed, which showed bilateral bright punctate window defects resulting in a speckled appearance throughout the fundus and pigmentary clumping mostly in the midperiphery ( Figure 2 , A and B).
Spectral domain optical coherence tomography demonstrated thinning of the retina, especially in the outer nuclear layer, which corresponds to loss of photoreceptors ( Figure 2 , C and D). Visual field test (Goldmann perimetry) showed areas of paracentral scotomas. The patient subsequently underwent electroretinogram (ERG) testing. Pattern ERG P50 was undetectable bilaterally. Rod ERGs were severely subnormal bilaterally. Bright flash ERG a-waves were markedly subnormal and waveforms electoronegative bilaterally. Photopic 30 Hz flicker ERGs (EPIC-4000 system, LKC Technologies, West Midlands, United Kingdom) were markedly delayed and of subnormal amplitude bilaterally. Single-flash cone ERGs have an abnormal broad a-wave and sharply rising b-wave without oscillatory potentials and both a-and b-wave amplitudes were subnormal bilaterally. These ERG features were consistent with a rod-cone dystrophy with an additional inner retinal involvement suggestive of retinal toxicity.
The diagnosis of toxic retinopathy associated with ritonavir was made based on clinical history, examination, and ophthalmologic examinations.
Discussion
Many etiologies can cause retinopathy phenocopying retinitis pigmentosa (pseudoretinitis pigmentosa). Correctly differentiating these conditions from RP is imperative because these conditions are generally treatable, unlike RP. The causes of pseudoretinitis pigmentosa, based on etiology, include infection such as congenital rubella, toxoplasmosis, syphillis, Lyme disease; inflammation (retinal vasculitis, old posterior uveitis); autoimmunity (autoimmune retinopathy, cancer-associated retinopathy, acute zonal occult outer retinopathy); trauma (intraocular foreign bodies such as siderosis, or blunt trauma, such as severe commotio retinae); and drug toxicity to chloroquine/hydrohychloroquine, phenothiazides, or thioridazine. 8 In the present case, the combination of a good clinical history and a complete ophthalmic examination contributed significantly to diagnosis.
Three drugs used in the treatment of AIDS-related disorders have previously been linked with retinal epitheliopathy: the protease inhibitor ritonavir; clofazimine, used in the management of atypical mycobacterial infections, and the reverse transcriptase inhibitor didanosine. 5 The only agent common to our patient and previous cases is ritonavir, an HIV protease inhibitor, which exhibits antineoplastic effects independent from its ability to inhibit HIV protease. 9 Ocular complications resulting from ritonavir are rare and can include blepharitis, conjunctivitis, iritis, and uveitis. 10 Roe et al 11 reported the occurrence of a retinal pigment epitheliopathy associated with macular telangiectasis and intraretinal crystal deposits in HIV-positive patients receiving long-term ritonavir as part of highly active antiretroviral therapy. Both hypertrophic and atrophic changes were seen; and these did not involve the fovea. Intraretinal crystalline deposits and other features reminiscent of idiopathic parafoveal telangiectasis were also seen, in all 3 patients. However, none of these cases involving ritonavir toxicity described fundus appearance mimicking a pseudoretinitis pigmentosa fundus. Retinitis pigmentosa-like fundus has been reported by Muccioli et al 12 in an HIV-positive patient and it was attributed to didanosine use; however, this patient was on ritonavir therapy too.
It is not yet known the mechanism by which ritonavir injures the RPE, the neurosensory retina, and the choriocapillaris, but it seems to be related to the drug's effect on mitochondrial DNA. Based on rodent studies, the proposed mechanism of ritonavir retinal toxicity has been phospholipidosis. 13 Besides the retina, liver, thyroid, and kidney have also been described as targets for dose-related ritonavir toxicity. 13 Liver dysfunction was one characteristic common to the 3 patients in Roe's report 11 ; whereas our patient had normal liver serum enzymes, thyroid hormone blood tests, and blood and urine kidney function tests.
Fundus autofluorescence is a useful tool because it displayed a more extensive disruption of the RPE than stereo fundus biomicroscopy alone. The involvement of the macula of the right eye explains the poorer vision in that eye compared with the left eye, where the macula seems to have normal fundus autofluorescence.
This report shows the need for ophthalmologic screening and constant monitoring of patients using None of the authors have any financial/conflicting interests to disclose.
Reprint requests: Evangelia Papavasileiou, MD, PhD, Western Eye Hospital, Imperial College Ophthalmic Research Group, Clinical Trials Unit, 3rd floor, Marylebone Road, London NW1 5QH, United Kingdom; e-mail: liapapava@hotmail.com the ritonavir for early detection of possible retinal toxicity. Identification of this is important, especially if a reasonable alternative is available. Our case report may represent further evidence toward the retinal toxicity of the protease inhibitor ritonavir. To the best of our knowledge, this is the first case report of ritonavir toxicity with fundus appearance mimicking a pseudoretinitis pigmentosa fundus. 
